Literature DB >> 11606762

Th1-polarizing immunization with egg antigens correlates with severe exacerbation of immunopathology and death in schistosome infection.

L I Rutitzky1, H J Hernandez, M J Stadecker.   

Abstract

In schistosomiasis mansoni, parasite eggs precipitate an intrahepatic granulomatous and fibrosing inflammatory process, which is mediated by, and dependent on, MHC class II-restricted CD4 T helper (Th) lymphocytes specific for schistosome egg antigens (SEA). In the mouse model of the disease, CBA mice develop large granulomas, whereas in C57BL/6 (BL/6) mice these granulomas are significantly smaller. To further investigate how the prevailing cytokine environment influences the development of the egg-induced immunopathology, we immunized the low-pathology BL/6 mice with SEA in complete Freund's adjuvant (CFA) once before, and once again during, the course of a 7-week infection. This immunization caused a pronounced Th1 shift in the SEA-specific CD4 T cell response, which was detected in the mesenteric lymph nodes (MLNs) and spleens, as well as in the granulomatous lesions themselves. The immunized mice displayed a dramatic enhancement of hepatic egg-induced immunopathology manifested by a marked increase in granuloma size and parenchymal inflammation, leading to early death. Control mice immunized with equivalent amounts of SEA or CFA alone displayed the smaller hepatic lesions in a Th2-dominant environment typically seen in the unimmunized BL/6 mice. Analysis of granuloma and MLN lymphocytes from the SEA/CFA-immunized mice revealed that the proportion of CD4 T cells was unchanged in comparison with the control BL/6 groups and remained significantly lower than that seen in the normally high-pathology CBA strain. These results suggest that the shift toward Th1-type cytokine production by a numerically stable population of CD4 T cells correlates with severe exacerbation of immunopathology in schistosomiasis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11606762      PMCID: PMC60855          DOI: 10.1073/pnas.231258498

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  46 in total

Review 1.  Other functions, other genes: alternative activation of antigen-presenting cells.

Authors:  S Goerdt; C E Orfanos
Journal:  Immunity       Date:  1999-02       Impact factor: 31.745

2.  High levels of TNF, soluble TNF receptors, soluble ICAM-1, and IFN-gamma, but low levels of IL-5, are associated with hepatosplenic disease in human schistosomiasis mansoni.

Authors:  J K Mwatha; G Kimani; T Kamau; G G Mbugua; J H Ouma; J Mumo; A J Fulford; F M Jones; A E Butterworth; M B Roberts; D W Dunne
Journal:  J Immunol       Date:  1998-02-15       Impact factor: 5.422

3.  Th2 cells are required for the Schistosoma mansoni egg-induced granulomatous response.

Authors:  M H Kaplan; J R Whitfield; D L Boros; M J Grusby
Journal:  J Immunol       Date:  1998-02-15       Impact factor: 5.422

4.  IL-10 deficit correlates with chronic, hypersplenomegaly syndrome in male CBA/J mice infected with Schistosoma mansoni.

Authors:  S C Bosshardt; G L Freeman; W E Secor; D G Colley
Journal:  Parasite Immunol       Date:  1997-08       Impact factor: 2.280

5.  Experimental murine schistosomiasis in the absence of B7 costimulatory molecules: reversal of elicited T cell cytokine profile and partial inhibition of egg granuloma formation.

Authors:  H J Hernandez; A H Sharpe; M J Stadecker
Journal:  J Immunol       Date:  1999-03-01       Impact factor: 5.422

6.  Human Schistosomiasis mansoni: IL-10 modulates the in vitro granuloma formation.

Authors:  P L Falcão; L C Malaquias; O A Martins-Filho; A M Silveira; V M Passos; A Prata; G Gazzinelli; R L Coffman; R Correa-Oliveira
Journal:  Parasite Immunol       Date:  1998-10       Impact factor: 2.280

7.  Schistosoma mansoni: genetic restriction and cytokine profile of the CD4 + T helper cell response to dominant epitope peptide of major egg antigen Sm-p40.

Authors:  H J Hernandez; C M Edson; D A Harn; C J Ianelli; M J Stadecker
Journal:  Exp Parasitol       Date:  1998-09       Impact factor: 2.011

Review 8.  Cytokines as determinants of resistance and pathology in human Schistosoma mansoni infection.

Authors:  R Corrêa-Oliveira; L C Malaquias; P L Falcão; I R Viana; L M Bahia-Oliveira; A M Silveira; L A Fraga; A Prata; R L Coffman; J R Lambertucci; J R Cunha-Melo; O A Martins-Filho; R A Wilson; G Gazzinelli
Journal:  Braz J Med Biol Res       Date:  1998-01       Impact factor: 2.590

Review 9.  The immune response and immunopathology in infection with Schistosoma mansoni: a key role of major egg antigen Sm-p40.

Authors:  M J Stadecker; H J Hernandez
Journal:  Parasite Immunol       Date:  1998-05       Impact factor: 2.280

10.  T cells expressing the gamma delta T cell receptor are not required for egg granuloma formation in schistosomiasis.

Authors:  J Iacomini; D E Ricklan; M J Stadecker
Journal:  Eur J Immunol       Date:  1995-04       Impact factor: 5.532

View more
  35 in total

1.  The pathogenic Th17 cell response to major schistosome egg antigen is sequentially dependent on IL-23 and IL-1β.

Authors:  Mara G Shainheit; Krzysztof W Lasocki; Eduardo Finger; Bridget M Larkin; Patrick M Smith; Arlene H Sharpe; Charles A Dinarello; Laura I Rutitzky; Miguel J Stadecker
Journal:  J Immunol       Date:  2011-10-14       Impact factor: 5.422

2.  B10 cells induced by Schistosoma japonicum soluble egg antigens modulated regulatory T cells and cytokine production of T cells.

Authors:  Fang Tian; Xueli Hu; Kangwen Xian; Dayuan Zong; Hao Liu; Hui Wei; Weiping Yang; Li Qian
Journal:  Parasitol Res       Date:  2015-07-08       Impact factor: 2.289

3.  IFN-γ-driven IDO production from macrophages protects IL-4Rα-deficient mice against lethality during Schistosoma mansoni infection.

Authors:  Reena Rani; Michael B Jordan; Senad Divanovic; De'Broski R Herbert
Journal:  Am J Pathol       Date:  2012-03-16       Impact factor: 4.307

4.  IL-4 and IFN-γ induced by human immunodeficiency virus vaccine in a schistosome infection model.

Authors:  Jiangmei Yin; Anlan Dai; Tatiana Arango; Ravi S Kasinathan; Robert M Greenberg; Jean D Boyer
Journal:  Hum Vaccin Immunother       Date:  2012-11-01       Impact factor: 3.452

Review 5.  Induction and regulation of pathogenic Th17 cell responses in schistosomiasis.

Authors:  Bridget M Larkin; Patrick M Smith; Holly E Ponichtera; Mara G Shainheit; Laura I Rutitzky; Miguel J Stadecker
Journal:  Semin Immunopathol       Date:  2012-10-25       Impact factor: 9.623

6.  Dendritic cell expression of the C-type lectin receptor CD209a: A novel innate parasite-sensing mechanism inducing Th17 cells that drive severe immunopathology in murine schistosome infection.

Authors:  Holly E Ponichtera; Miguel J Stadecker
Journal:  Exp Parasitol       Date:  2015-04-23       Impact factor: 2.011

7.  TH1-dominant granulomatous pathology does not inhibit fibrosis or cause lethality during murine schistosomiasis.

Authors:  Mosiuoa Leeto; De'Broski R Herbert; Reece Marillier; Anita Schwegmann; Lizette Fick; Frank Brombacher
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

8.  Dendritic cell IL-23 and IL-1 production in response to schistosome eggs induces Th17 cells in a mouse strain prone to severe immunopathology.

Authors:  Mara G Shainheit; Patrick M Smith; Lindsey E Bazzone; Andrew C Wang; Laura I Rutitzky; Miguel J Stadecker
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

9.  IL-4R alpha expression by bone marrow-derived cells is necessary and sufficient for host protection against acute schistosomiasis.

Authors:  De'Broski R Herbert; Tatyana Orekov; Charles Perkins; Marc E Rothenberg; Fred D Finkelman
Journal:  J Immunol       Date:  2008-04-01       Impact factor: 5.422

10.  T-bet protects against exacerbation of schistosome egg-induced immunopathology by regulating Th17-mediated inflammation.

Authors:  Laura I Rutitzky; Patrick M Smith; Miguel J Stadecker
Journal:  Eur J Immunol       Date:  2009-09       Impact factor: 5.532

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.